Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Early Switch in Moderate ARDS (SWITCH-ARDS)

13 novembre 2026 aggiornato da: DEMOSTHENES MAKRIS, University of Thessaly

Early Switch to Assisted Ventilation in Patients With Moderate ARDS: a Physiological Study

The optimal timing for transition from controlled to assisted mechanical ventilation in patients with acute respiratory distress syndrome (ARDS) remains uncertain. Excessive spontaneous respiratory effort may promote injurious transpulmonary pressure swings and heterogeneous regional ventilation, whereas unnecessary prolongation of controlled ventilation may increase sedation exposure and diaphragmatic dysfunction.

This prospective, single-center physiological interventional study will enroll mechanically ventilated adults with ARDS and a PaO₂/FiO₂ ratio >100 and ≤200 mmHg, measured during PEEP=5 cmH2O, who are receiving controlled mechanical ventilation. Participants will undergo a protocolized 30-minute transition from controlled to assisted mechanical ventilation after reduction of sedation sufficient to allow spontaneous respiratory activity.

Respiratory effort and drive, airway and esophageal pressures, respiratory flow, respiratory mechanics, gas exchange, and regional ventilation measured by electrical impedance tomography will be assessed before and during the transition. Participants will subsequently be followed for 48 hours to determine whether assisted ventilation can be maintained without return to fully controlled mechanical ventilation.

Panoramica dello studio

Descrizione dettagliata

Participants meeting eligibility criteria will initially remain on their clinically prescribed controlled mechanical ventilation. Sedation will be gradually reduced to permit the reappearance of spontaneous respiratory activity while avoiding clinically significant agitation or patient-ventilator dyssynchrony. Once spontaneous respiratory activity is present, participants will be transitioned to assisted mechanical ventilation. Positive end-expiratory pressure will be maintained at the pre-transition level, which will have been titrated with the use of esophageal manometry so as to achieve an end-expiratory trans-pulmonary pressure above 0 cmH2O, and inspired oxygen fraction will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain protective targets: esophageal pressure swings= 3-15 cmH2O (diaphragm protective) and transpulmonary pressure swings < 15-20 cmH2O (lung protective).

The physiological transition trial will last 30 minutes. Continuous recordings of airway pressure, esophageal pressure, respiratory flow, and electrical impedance tomography will be obtained. Respiratory drive will additionally be assessed using airway occlusion pressure at 100 milliseconds (P0.1).

Three prespecified analysis periods will be used: T0, the final 5 minutes during controlled ventilation before transition; T1, the first 5 minutes of assisted ventilation; and T2, minutes 25-30 of assisted ventilation.

Electrical impedance tomography analyses will include regional distribution of tidal ventilation, global inhomogeneity index, end-expiratory lung impedance, ventral-to-dorsal ventilation distribution, center of ventilation, and occurrence or magnitude of pendelluft. Respiratory mechanics analyses will include esophageal pressure swing, pressure-time product of the esophageal pressure, transpulmonary pressure, respiratory system elastance, chest-wall elastance, and lung elastance.

The transition trial will be stopped if prespecified clinical intolerance or safety criteria occur. Participants who do not tolerate the trial will be returned to controlled ventilation according to clinical requirements.

After completion of the 30-minute trial, participants will be followed for 48 hours. Successful transition will be defined as maintenance of assisted mechanical ventilation without the need to return to fully controlled mechanical ventilation during this period.

Tipo di studio

Osservativo

Iscrizione (Stimato)

30

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Apostolos - Alkiviadis Menis, MD, PhD
  • Numero di telefono: +30 2413501280
  • Email: menis.ap.alk@proton.me

Backup dei contatti dello studio

Luoghi di studio

      • Larissa, Grecia
        • Reclutamento
        • Critical Care Department, University Hospital of Larisa
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Patients with ARDS of severe to moderate severity (100<PaO2/FiO2<200 mmHg).

Descrizione

Inclusion Criteria:

  • Age ≥18 years
  • Endotracheally intubated and receiving invasive mechanical ventilation
  • Meets diagnostic criteria for acute respiratory distress syndrome
  • PaO₂/FiO₂ ratio >100 and ≤200 mmHg
  • Receiving controlled mechanical ventilation immediately before the transition trial

Exclusion Criteria:

  • Implanted electrical cardiac or other device incompatible with electrical impedance tomography
  • Thoracic drains, extensive dressings, or other factors preventing appropriate EIT belt placement
  • Contraindication to placement of an esophageal balloon catheter
  • Active neuromuscular blockade at initiation of the transition trial
  • Significant hemodynamic instability
  • Any clinical condition for which reduction of sedation or transition to assisted ventilation is considered unsafe by the treating physician

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Experimental: Protocolized Transition to Assisted Mechanical Ventilation

Participants receiving controlled mechanical ventilation will undergo gradual reduction of sedation to permit spontaneous respiratory activity, followed by a 30-minute transition to assisted mechanical ventilation. PEEP will remain at the pre-transition value and FiO₂ will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain tidal volume at approximately 6-8 mL/kg predicted body weight. Physiological measurements will be recorded continuously, and the procedure will be terminated if prespecified intolerance or safety criteria occur.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Lasso di tempo: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure respiratory rate (breaths per minute).

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Lasso di tempo: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the lung elastance, the chest wall elastance and the total respiratory system elastance (all measured in cmH₂O/L).

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Lasso di tempo: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the transpulmonary pressure, which is measured in cmH₂O. During the baseline measurement both statics and dynamics measurements will be calculated, whereas during the assisted phase the investigator will include only the dynamic measurements.

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Lasso di tempo: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure tidal volume (mLs).

During the first thirty minutes of assisted ventilation.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Lasso di tempo: During the first thirty minutes of assisted ventilation.

The investigator will measure the variation in the global inhomogeneity index derived by using electrical impedance tomography.

During the first thirty minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Lasso di tempo: During the first 30-minutes of assisted ventilation.

The investigator will measure the end-expiratory lung impedance, EELI, which is measured in ohms.

During the first 30-minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Lasso di tempo: During the first 30-minutes of assisted ventilation.

The investigator will measure the ventral to dorsal ratio using the electrical impedance tomography.

During the first 30-minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Lasso di tempo: During the first 30-minutes of assisted ventilation.

The investigator will measure the variation in the pendelluft phenomenon using the impedance amplitude values.

During the first 30-minutes of assisted ventilation.
Differences in respiratory effort between successful and failed transition to assisted ventilation
Lasso di tempo: During the first 30-minutes of assisted ventilation.

The investigator will measure the differences in esophageal pressure swings, ΔPes in cmH₂O, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial.

During the first 30-minutes of assisted ventilation.
Differences in respiratory effort between successful and failed transition to assisted ventilation.
Lasso di tempo: During the first 30-minutes of assisted ventilation.

The investigator will measure the differences in the esophageal pressure-time product measured in cmH₂O⋅s/min, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial.

During the first 30-minutes of assisted ventilation.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Apostolos - Alkiviadis Menis, MD, PhD, General University Hospital of Larisa, University of Thessaly
  • Direttore dello studio: Makris, MD, PhD, General University Hospital of Larisa, University of Thessaly

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 novembre 2026

Completamento primario (Stimato)

1 ottobre 2028

Completamento dello studio (Stimato)

1 dicembre 2028

Date di iscrizione allo studio

Primo inviato

8 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

23 ottobre 2026

Primo Inserito (Effettivo)

30 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi